NASDAQ:ALLR Allarity Therapeutics (ALLR) Stock Price, News & Analysis $1.60 -0.04 (-2.44%) (As of 10/8/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Allarity Therapeutics Stock (NASDAQ:ALLR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Allarity Therapeutics alerts:Sign Up Key Stats Today's Range$1.57▼$1.6950-Day Range$0.11▼$3.7952-Week Range$1.57▼$666.00Volume76,015 shsAverage Volume209,899 shsMarket Capitalization$28.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAllarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Read More… [SHOCKING] Crypto Document Leak… (Ad)The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around the corner. That's why we're offering you instant access to the game-changing book that's transforming average investors into massive crypto successes.Download your digital copy now Allarity Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks6th Percentile Overall ScoreALLR MarketRank™: Allarity Therapeutics scored higher than 6% of companies evaluated by MarketBeat, and ranked 970th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Allarity Therapeutics.Read more about Allarity Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Allarity Therapeutics are expected to grow in the coming year, from ($78.08) to ($46.85) per share.Read more about Allarity Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.92% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently increased by 392.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.92% of the float of Allarity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllarity Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Allarity Therapeutics has recently increased by 392.71%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.10 News SentimentAllarity Therapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Allarity Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ALLR on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows2 people have added Allarity Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.08% of the stock of Allarity Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.53% of the stock of Allarity Therapeutics is held by institutions.Read more about Allarity Therapeutics' insider trading history. Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLR Stock News HeadlinesALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud LawsuitOctober 8 at 3:48 PM | prnewswire.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity TherapeuticsOctober 7 at 5:24 AM | markets.businessinsider.comMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.October 8, 2024 | Paradigm Press (Ad)ROSEN, SKILLED INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLROctober 6 at 8:38 AM | globenewswire.comALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud LawsuitOctober 3, 2024 | prnewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor ProgramOctober 3, 2024 | finanznachrichten.deALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud LawsuitOctober 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLROctober 3, 2024 | prnewswire.comSee More Headlines ALLR Stock Analysis - Frequently Asked Questions How have ALLR shares performed this year? Allarity Therapeutics' stock was trading at $11.0220 at the start of the year. Since then, ALLR stock has decreased by 85.5% and is now trading at $1.60. View the best growth stocks for 2024 here. How were Allarity Therapeutics' earnings last quarter? Allarity Therapeutics, Inc. (NASDAQ:ALLR) released its quarterly earnings results on Monday, August, 5th. The company reported ($0.11) earnings per share for the quarter. When did Allarity Therapeutics' stock split? Allarity Therapeutics shares reverse split on Wednesday, September 11th 2024. The 1-30 reverse split was announced on Wednesday, September 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Allarity Therapeutics? Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/05/2024Today10/08/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLR CUSIPN/A CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,078.75% Return on Assets-67.89% Debt Debt-to-Equity RatioN/A Current Ratio2.01 Quick Ratio2.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($559.31) per share Price / Book0.00Miscellaneous Outstanding Shares17,607,000Free Float17,593,000Market Cap$29.39 million OptionableNot Optionable Beta0.30 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:ALLR) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
